

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/512,736 02/24/2000		Mich B. Hein	TSRI-184.2con4	TSRI-184.2con4 5292		
30542	7590	07/01/2004		EXAM	EXAMINER	
FOLEY &		ER	COLLINS, C	COLLINS, CYNTHIA E		
P.O. BOX 80278 SAN DIEGO, CA 92138-0278				ART UNIT	PAPER NUMBER	
				1638		

DATE MAILED: 07/01/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)				
Office Addison Commencers	09/512,736	HEIN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Cynthia Collins	1638				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply if NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed is will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on <u>02 M</u>	arch 2004.					
2a) This action is FINAL . 2b) ☑ This	This action is FINAL . 2b)⊠ This action is non-final.					
<i>,</i> —	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) <u>53,56,63-65,67,68,76 and 85-92</u> is/are 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) <u>53,56,63-65,67,68,76 and 85-92</u> is/are 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	vn from consideration.					
Application Papers						
 9) The specification is objected to by the Examiner 10) The drawing(s) filed on 24 February 2000 is/are Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examiner 	e: a)⊠ accepted or b)⊡ objected drawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of the certified copies. 	s have been received. s have been received in Applicati ity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da					

Art Unit: 1638

r. . . .

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 2, 2004 has been entered.

Claims 1-52, 54-55, 57-62, 66, 69-75 and 77-84 are cancelled.

Claim 53 is presently amended.

Claims 85-92 are newly added.

Claims 53, 56, 63-65, 67-68, 76 and 85-92 are pending and are examined.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

All previous objections and rejections not set forth below have been withdrawn.

Response to Amendment

The amendment to the claims filed on March 2, 2004 does not comply with the requirements of 37 CFR 1.121(c) because the status of claim 66, cancelled in the amendment filed on March 19, 2002, is not indicated.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1638

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 85, and claims 86-92 dependent thereon, are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. The limitations "at least the antigen specific portion of an immunoglobulin light chain" and "wherein said light chain and said heavy chain are the product of a lymphoid cell producing an antigen-specific immunoglobulin" recited in claim 85 do not find support in the specification as originally filed, and thus constitute new matter.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 53, and claims 56, 63-65, 67-68 and 76 dependent thereon, are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 53 is indefinite in the recitation of "said plant cell" in line 12. It is unclear whether the "said plant cell" refers to "A plant cell" in the preamble of the claim, or whether "said plant cell" refers to "a plant cell" in lines 10-11 of the body of the claim. It is suggested that the claim be amended to indicate whether "said plant cell" in line 12 refers to "A plant cell containing nucleotide

Art Unit: 1638

sequence encoding an immunoglobulin product" or "a plant cell in which at least a portion of the variable region of an immunoglobulin light chain is coexpressed".

Claims 53 and 85, and claims 56, 63-65, 67-68, 76 and 86-92 dependent thereon, are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 53 and 85 are indefinite in the recitation of "wherein said plant cell does not contain nucleotide sequence encoding said immunoglobulin heavy chain" in lines 12 and 7 respectively. It is unclear whether the plant cell does not contain any nucleotide sequence encoding an immunoglobulin heavy chain, or whether the plant cell does not contain the nucleotide sequence encoding the specific heavy chain from the particular antigen-specific immunoglobulin that the light chain is obtained from (claim 53) or with which the antigen specific portion of the light chain is capable of assembly (claim 85). In this regard it is noted that the instant application was restricted to plant cells containing nucleotide sequences encoding light chain immunoglobulin polypeptides only. The recitation of "said immunoglobulin heavy chain" allows for a claim interpretation in which the plant cell may comprise other nucleotide sequences encoding other heavy chain polypeptides. It is suggested that the claims be amended to recite "an" rather than "said" in order to overcome the rejection.

Claim 85, and claims 86-92 dependent thereon, are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 85 is indefinite in the recitation of "said

Art Unit: 1638

antigen specific portion of the light chain being capable of assembly with an immunoglobulin heavy chain", since the capacity of an immunoglobulin light chain to assemble with an immunoglobulin heavy chain resides outside of the antigen specific portion of the light chain.

Claim 88 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 88 is indefinite because it lacks a transitional phrase between "said nucleotide sequence" and "a variable region". The scope of the claim is unclear in the absence of a transitional phrase between the preamble and the body of the claim.

Remarks

Claims 53, 56, 63-65, 67-68, 76 and 85-92 are rejected.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cynthia Collins whose telephone number is (571) 272-0794. The examiner can normally be reached on Monday-Friday 8:45 AM -5:15 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (571) 272-0804. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1638

Page 6

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Agrithia Collins 6/24/04

Cynthia Collins